You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: RE47301

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE47301 protect, and when does it expire?

Patent RE47301 protects LEXISCAN and is included in one NDA.

This patent has twenty-eight patent family members in eighteen countries.

Summary for Patent: RE47301

Patent landscape, scope, and claims:

Title:	Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Abstract:	Disclosed is a synthesis suitable for large scale manufacture of an A.sub.2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
Inventor(s):	Zablocki; Jeff (Los Altos, CA), Elzein; Elfatih (Mountain House, CA), Seemayer; Robert (Belmont, CA), Lemons; Travis (Los Gatos, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	15/653,860
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE47301
Patent Claim Types: see list of patent claims	Composition; Process;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent RE47301

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008	AP	RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent RE47301

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007212542	⤷ Subscribe
Canada	2640089	⤷ Subscribe
Canada	2787759	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.